Recently, small molecules inhibiting the Shh pathway, including vismodegib (9) and sonidegib (10), have been approved by the Food and Drug Administration (FDA) for locally advanced and metastatic BCC. This evidence concerns the gene SHH and skin basal cell carcinoma.